Vraylar is going to crush Latuda sales

Discussion in 'Sunovion' started by anonymous, May 29, 2019 at 7:52 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Vraylar is going to crush Latuda sales.
     

  2. anonymous

    anonymous Guest

    OK thanks
     
  3. anonymous

    anonymous Guest

    lurasidone will be competitive on price
     
  4. anonymous

    anonymous Guest

    LMAO. Guess you must be on vray vray to be thinking that.... And, it's obviously not doing a thing for ya... Good luck with life
     
  5. anonymous

    anonymous Guest

    With what it’s akathisia rates, long half life + active metabolites, 1 dose strength efficacy or weak sales force? Haha, we’re trembling!
     
  6. anonymous

    anonymous Guest

    Hey, we here at Sunovion are still big pharma and we do what we do. Check boxes, sample drop, get signatures, drop off coffee and donuts and our calls are only about 2 minutes long. 8 Calls a day and done by 2 pm when the drug sells itself is what makes mamma happy. Heck I can even get in a yoga class before 3 pm before going home to let the nanny off. Hello Fresh for the hubby by 6 pm, get the girls down by 8 pm, watch a little TV or Netflix and in the bed by 9 pm. Repeat the next day!!!
     
  7. anonymous

    anonymous Guest

    The only 2 minute calls I get are at a lunch, other than that they are 20 seconds.
     
  8. anonymous

    anonymous Guest

    Your gravy train will soon end, you will unexpectedly arrive home at noon instead of 2pm, and then you’ll realize hubby been banging the nanny while you were delivering donuts
     
  9. anonymous

    anonymous Guest

    Vraylar will take 25% market share from Latuda in 60 days. Get your resumes ready
     
  10. anonymous

    anonymous Guest

    Lonhala sales will pick up the slack. No worries.
     
  11. anonymous

    anonymous Guest

     
  12. anonymous

    anonymous Guest

    Any head to head studies to prove your statement. NO pharma never pays for a study against the market share leader. So coverage better, I don't think so. Doc's will write it because its advertised and its something different.

    Is this drug different? Does it have a high powered Study? Fill us in.
     
  13. anonymous

    anonymous Guest

    maybe in your territory, VRY will have 25% market share, because you will be exposed as the inept & ineffective TS that you are-get your resume ready, homey!
     
  14. anonymous

    anonymous Guest

    Only thing stopping vraylar from taking market share from Latuda is their lack of skilled reps.

    Latuda became what it is today based on its salesforce.
     
  15. anonymous

    anonymous Guest

    8.1. Pregnancy.
    “Based on animal data may cause fetal harm”

    So doctor did you have a better choice in bipolar med for my client?

    Her baby has serious fetal harm while she was on Vyrlar.
     
  16. anonymous

    anonymous Guest

     
  17. anonymous

    anonymous Guest

    vraylar will have a black box warning because of fetal abnormalities.

    Soon
     
  18. anonymous

    anonymous Guest

    Black box warning coming for V

    Fetal abnormalities
     
  19. anonymous

    anonymous Guest

     
  20. anonymous

    anonymous Guest

    Milage log of every stop...:eek: dumb.